Distortion product otoacoustic emission for the screening of cochlear damage in children treated with cisplatin.

Objective: To detect subtle hearing changes by measuring otoacoustic emissions in patients treated with a first dose of cisplatin.

Methods: Prospective study. Methods: We recruited 26 patients (mean age at treatment, 11.3 years) into this prospective study conducted at a tertiary academic referral center. Audiograms and transient-evoked otoacoustic emissions (TEOAEs) and distortion-product otoacoustic emissions (DPOAEs) were measured before and after the first dose of cisplatin.

Results: Baseline readings were compared with those recorded after the administration of the first dose of cisplatin. Two patients showed a loss of TEOAEs at high frequencies above 4 kHz, and this was consistent with the 25-dB hearing loss of the high frequencies detected in their audiograms; there was a significant threshold shift for DPOAEs at a frequency >3 to 4 kHz (P <.05).

Conclusions: DPOAE testing appears to be a more sensitive method to detect cochlear damage than conventional pure-tone audiometry. Our results suggest that the measurement of DPOAE thresholds is a useful approach to detect the early auditory changes induced by cisplatin therapy.